TAKEDA PHARMACEUTICAL CO LTD(TAK)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,212 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
TAK Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for TAKEDA PHARMACEUTICAL CO LTD (TAK), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TAK at 38.1/100 on a 32-signal composite quality model, placing it at rank #2,212 of 2,961 stocks — the bottom half of the AI-ranked universe. Top institutional holders of TAK by reported 13-F value include Capital Research Global Investors, FMR, MORGAN STANLEY, based on the most recent SEC filings. TAK trades on the NYSE exchange and files with the SEC under CIK 1395064. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TAK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TAKEDA PHARMACEUTICAL CO LTD directly from SEC EDGAR. TAKEDA PHARMACEUTICAL CO LTD's 13F Pro composite quality score has ranged between 37 and 39 since 2026, currently 38.1 — a stable long-term trajectory across 47 quarterly and live scoring snapshots.
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+7.5% YoYTotal Assets
-5.7% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $4.58T +7.5% | $4.26T +5.9% | $4.03T +12.8% | $3.57T +11.6% | $3.20T -2.8% | $3.29T |
| Total Assets | $14.25T -5.7% | $15.11T +8.2% | $13.96T +5.9% | $13.18T +2.1% | $12.91T +0.7% | $12.82T |
AI Insight: TAK Financial Trends
Insufficient financial data to assess Takeda's operational or financial trends.
• No financial metrics available across all periods (Q1 2019–Q1 2025). Data required to evaluate revenue, profitability, cash generation, or leverage trends.
⚠ Complete absence of quarterly financials prevents assessment of margin trajectory, debt dynamics, or cash flow sustainability.
AI Insight: TAK Ratio Trends
Insufficient data: all ratio fields are empty across the entire period, preventing trend analysis.
• No operating margin, net profit margin, ROE, ROA, ROIC, or debt-to-equity figures available for any quarter Q1 2019–Q1 2025.
⚠ Data completeness issue must be resolved to assess profitability, returns, and leverage trends.
Get alerted when TAK's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for TAKEDA PHARMACEUTICAL CO LTD including:
Top Institutional Holders of TAK
Capital Research Global Investors
$309.3M19,297,680 shFMR LLC
$153.9M9,599,302 shMORGAN STANLEY
$112.1M6,994,924 shADAGE CAPITAL PARTNERS GP, L.L.C.
$97.0M6,050,771 shGOLDMAN SACHS GROUP INC
$82.2M5,125,032 shPacer Advisors, Inc.
$79.7M2,515,027 shBRANDES INVESTMENT PARTNERS, LP
$72.8M4,539,347 shARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$59.8M3,732,924 shBlackRock, Inc.
$59.1M3,688,166 shRENAISSANCE TECHNOLOGIES LLC
$41.2M2,568,000 sh
| Fund | Value | Shares |
|---|---|---|
| Capital Research Global Investors | $309.3M | 19,297,680 |
| FMR LLC | $153.9M | 9,599,302 |
| MORGAN STANLEY | $112.1M | 6,994,924 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $97.0M | 6,050,771 |
| GOLDMAN SACHS GROUP INC | $82.2M | 5,125,032 |
| Pacer Advisors, Inc. | $79.7M | 2,515,027 |
| BRANDES INVESTMENT PARTNERS, LP | $72.8M | 4,539,347 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $59.8M | 3,732,924 |
| BlackRock, Inc. | $59.1M | 3,688,166 |
| RENAISSANCE TECHNOLOGIES LLC | $41.2M | 2,568,000 |
Companies Similar to TAK
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
KONINKLIJKE PHILIPS NV
SMITH & NEPHEW PLC
GSK plc
ASTRAZENECA PLC
SHINHAN FINANCIAL GROUP CO LTD
BP PLC
DR REDDYS LABORATORIES LTD
NatWest Group plc
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put TAK on your watchlist
Track score changes the day TAKEDA PHARMACEUTICAL CO LTD files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is TAK a good stock to buy?
13F Pro's AI-powered analysis of TAKEDA PHARMACEUTICAL CO LTD (TAK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TAK are available on the TAK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TAK is classified as a large company.
Which hedge funds own TAK?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TAK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of TAKEDA PHARMACEUTICAL CO LTD's investment landscape.